{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035556","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.344771+00:00","generated_at":"2026-06-04T15:27:54.040609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate","bullets":["Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).","Year-end cash $7.5M; subsequent ATM raised ~$4.5M.","Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.","FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.","EMA granted SME designation; additional microbiome data positive vs vancomycin."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035556","json":"https://secwatch.observer/filing/0001104659-24-035556.json","markdown":"https://secwatch.observer/filing/0001104659-24-035556.md","text":"https://secwatch.observer/filing/0001104659-24-035556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/tm249120d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:27:54.040609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bcd4f179deefd63b83e8021696636b06ebc0920","claim":"Acurx Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income $5.1 million, EPS $0.37 per diluted share.","evidence_excerpt":"The Company reported a net loss of $5.1 million or $0.37 per diluted share for the three months ended December 31, 2023 compared to a net loss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"$5.1 million"},{"label":"EPS","value":"$0.37 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cbd82b455019e7ec33155ae76bc9997ff756cf0a","claim":"Acurx Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $14.6.","evidence_excerpt":"oss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022, and a net loss of $14.6","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$14.6"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}